Marcin Jurga, Ph.D., Doctor of Medical Sciences; M.Sc.
Marcin Jurga specializes in adult stem cells biology, extracellular vesicles (EVs), tissue engineering and regenerative medicine. Marcin Jurga graduated at Warsaw University in Poland (2002) in the field of molecular biology. In 2007 Marcin Jurga got a Ph.D. in Medical Sciences at Medical Research Institute of Polish Academy of Sciences in Warsaw, Poland with specialty in human stem cell biology and tissue engineering. The post-doc study was performed at The Newcastle University, UK and at The Institute of Cell Research Therapy Lyon, France were Marcin Jurga coordinated international research projects focused on neural, pancreatic and bone tissue engineering and was involved in preparation of clinical trial in stem cell application in pediatric neurology. Since 2011 Marcin Jurga is the head of R&D at The Cell Factory biotech company in Niel, Belgium. The Cell Factory (www.cell-factory.com) focuses on development and bioproduction of new advanced medicinal products: stem cells and extracellular vesicles, and their application in regenerative medicine. Marcin Jurga is responsible for EVs products development (GLP), quality assurance, bioproduction process development (GMP) and clinical translation of the IMPs in accordance with the international regulations. Currently The Cell Factory is developing the EVs drugs: CF-MEV-107 for treatment of Crohn’s disease and CF-MEV-117 for treatment of drug resistant epilepsy. Marcin Jurga is also involved in business development and has participated in the recent deal of Esperite which secured external financing of up to EUR 13 million to support development of innovative technologies.
Bioproduction and Clinical Translation of Extracellular Vesicles for Treatment of Inflammatory Diseases
Wednesday, 27 September 2017 at 10:00
Add to Calendar ▼2017-09-27 10:00:002017-09-27 11:00:00Europe/LondonBioproduction and Clinical Translation of Extracellular Vesicles for Treatment of Inflammatory DiseasesExtracellular Vesicles 2017 in Cripps Court, Magdalene College, Cambridge, UKCripps Court, Magdalene College, Cambridge, UKSELECTBIOenquiries@selectbiosciences.com
Recent progress in development of experimental cell-based therapies demonstrated a promising efficacy of somatic cells in stimulation and modulation of tissue’s regenerative capabilities. Commercialization of cell therapeutics remains challenging mainly due to complex and expensive production process. It has been demonstrated that extracellular vesicles (EVs) could be an attractive alternative for many allogenic cell-based therapeutics. EVs are nanometer-size particles secreted by different types of cells in vivo and in vitro. EVs are presenting a similar therapeutic properties to the parent cells with several additional benefits: (i) manufacturing is more effective and cheaper, (ii) higher stability, (iii) lower immunogenicity, (iv) no risk of uncontrolled ectopic differentiation and proliferation, (v) better penetration into injury site e.g. cross BBB.
Add to Calendar ▼2017-09-27 10:00:002017-09-27 11:00:00Europe/LondonBioproduction and Clinical Translation of Extracellular Vesicles for Treatment of Inflammatory DiseasesExtracellular Vesicles 2017 in Cripps Court, Magdalene College, Cambridge, UKCripps Court, Magdalene College, Cambridge, UKSELECTBIOenquiries@selectbiosciences.com
